Analytical Data
-
Gene name
Ifi27l2a
- Application
-
Alternative Names
(Interferon-stimulated gene 12 protein)(ISG12)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8R412
-
Expression Region
25-90aa
-
Molecular Weight
7.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFI27L2A, also known as Interferon Inducible Protein 27-Like 2A, is a member of the interferon-stimulated gene (ISG) family and has garnered significant attention in the field of immunology and cancer research. It is primarily expressed in response to viral infections and plays a crucial role in the innate immune response. The IFI27L2A protein has been implicated in various cellular processes, including apoptosis, cell proliferation, and immune modulation. Recent studies have suggested that IFI27L2A may influence tumor progression and the tumor microenvironment by modulating immune responses, making it a potential biomarker for cancer diagnosis and prognosis. Furthermore, its role in the response to interferons positions it as a key player in antiviral defenses. Research has focused on characterizing the structure and function of the recombinant IFI27L2A protein to elucidate its mechanisms of action and explore its potential therapeutic applications. Understanding the pathways regulated by IFI27L2A could provide insights into new strategies for enhancing anti-tumor immunity and developing innovative treatments for cancer and viral infections. The recombinant form of this protein enables detailed functional assays and lays the groundwork for further studies aimed at targeting IFI27L2A in clinical applications. As such, continued research into IFI27L2A will not only deepen our understanding of immune responses but also potentially lead to novel therapeutic approaches in oncology and infectious diseases.
